Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study

Farawela, Hala M.; Zawam, Hamdy; Al-Wakeel, Hanan; El-Nagdy, Mona H.; Elrefaey, Fatma; Abdelrahman, Hala

doi:10.1080/00365513.2018.1555854

Cited by 2 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, SALL4 expression was higher among AML patients with CD34-positive expression than among those with CD34-negative expression, which may have a close correlation with a high capacity for self-renewal [183]. SALL4 has different effects on both proapoptotic and antiapoptotic pathways in normal and leukemic cells [189].…”

Section: Normal Hematopoietic Function and Leukemiamentioning

confidence: 97%

“…AML has a poor prognosis [183] and is a clonal disorder arising from the differentiation arrest of myeloid precursors and the malignant proliferation of bone marrow-derived, self-renewing stem or progenitor cells in the BM and blood [184]. Clinical sequelae generally include discomfort and fatigue, infection, bleeding and/or bruises, and often bone pain [185].…”

Section: Normal Hematopoietic Function and Leukemiamentioning

confidence: 99%

See 1 more Smart Citation

SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance

Sun

et al. 2022

IJMS

View full text Add to dashboard Cite

SALL4, a member of the SALL family, is an embryonic stem cell regulator involved in self-renewal and pluripotency. Recently, SALL4 overexpression was found in malignant cancers, including lung cancer, hepatocellular carcinoma, breast cancer, gastric cancer, colorectal cancer, osteosarcoma, acute myeloid leukemia, ovarian cancer, and glioma. This review updates recent advances of our knowledge of the biology of SALL4 with a focus on its mechanisms and regulatory functions in tumors and human hematopoiesis. SALL4 overexpression promotes proliferation, development, invasion, and migration in cancers through activation of the Wnt/β-catenin, PI3K/AKT, and Notch signaling pathways; expression of mitochondrial oxidative phosphorylation genes; and inhibition of the expression of the Bcl-2 family, caspase-related proteins, and death receptors. Additionally, SALL4 regulates tumor progression correlated with the immune microenvironment involved in the TNF family and gene expression through epigenetic mechanisms, consequently affecting hematopoiesis. Therefore, SALL4 plays a critical oncogenic role in gene transcription and tumor growth. However, there are still some scientific hypotheses to be tested regarding whether SALL4 is a therapeutic target, such as different tumor microenvironments and drug resistance. Thus, an in-depth understanding and study of the functions and mechanisms of SALL4 in cancer may help develop novel strategies for cancer therapy.

show abstract

Section: Normal Hematopoietic Function and Leukemiamentioning

confidence: 97%

Section: Normal Hematopoietic Function and Leukemiamentioning

confidence: 99%

SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance

Sun

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…another previous study demonstrated that Sall4 controls the stemness properties of embryonic stem cells at both the transcriptional and epigenetic levels via direct or indirect interaction with nanog and ocT4 (20). However, it has also been showed that Sall4 is re-expressed in various cancer types (11)(12)(13)(14)(15)(16) and was first recognized as an oncogene in leukemia (17,37). Yakaboski et al (38) found that in Sall4-positive Hcc, the expression of certain progenitor-like genes is high.…”

Section: Discussionmentioning

confidence: 99%

Expression and clinical value of SALL4 in renal cell carcinomas

Che

Wang

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

The aim of the present study was to investigate the expression of spalt like transcription factor 4 (SALL4) in the three most common types of renal cell carcinomas (rcc) [clear cell rcc (ccrcc), papillary renal cell carcinoma (prcc) and chromophobe rcc (chrcc)], and the association with the overall survival (oS) of patients. The cancer Genome atlas (TcGa) database and rcc samples were used to investigate the expression levels of the SALL4 gene and its association with the oS in the three types of rcc based on the analysis of the transcriptome, copy number and survival data. it was found that Sall4 was highly expressed in ccrcc and prcc tumor tissue, and low mrna expression level of SALL4 indicated a prolonged survival in both ccrcc and prcc. This mrna expression level was associated with pathological Tumor-node-Metastasis stage, M and T stages in both ccrcc and prcc. The analysis of the enriched pathway results suggested that Sall4 may act via translation initiation, and that the related genes promoted the progression of rcc. Moreover, the high expression level of Sall4 was detected in rcc samples and serum from patients. it was demonstrated that Sall4 promotes increased viability in rcc cells. Therefore, the present results suggest that Sall4 may be a sensitive and specific cancer biomarker in ccRCC and prcc. Furthermore, targeting of Sall4 may improve rcc therapy and prolong the survival of patients with ccrcc or prcc.

show abstract

Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study

Cited by 2 publications

References 29 publications

SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance

SALL4 Oncogenic Function in Cancers: Mechanisms and Therapeutic Relevance

Expression and clinical value of SALL4 in renal cell carcinomas

Contact Info

Product

Resources

About